Zeitschriftenaufsatz | 2021 Open Access

Immunologically relevant aspects of the new COVID-19 vaccines-an ÖGAI (Austrian Society for Allergology and Immunology) and AeDA (German Society for Applied Allergology) position paper.

Autor:in
Untersmayr, Eva; Förster-Waldl, Elisabeth; Bonelli, Michael; Boztug, Kaan; Brunner, Patrick M; Eiwegger, Thomas; Eller, Kathrin; Göschl, Lisa; Grabmeier-Pfistershammer, Katharina; Hötzenecker, Wolfram; Jordakieva, Galateja; Moschen, Alexander R; Pfaller, Birgit; Pickl, Winfried; Reinisch, Walter; Wiedermann, Ursula; Klimek, Ludger; Bergmann, Karl-Christian; Brehler, Randolf; Pfützner, Wolfgang; Novak, Natalija; Merk, Hans; Rabe, Uta; Schlenter, Wolfgang; Ring, Johannes; Wehrmann, Wolfgang; Mülleneisen, Norbert; Wrede, Holger; Fuchs, Thomas; Jensen-Jarolim, Erika
Publikationen als Autor:in / Herausgeber:in der Vetmeduni
Jensen-Jarolim, Erika
Journal
Allergo Journal International
Schlagwörter
MESSENGER-RNA VACCINES; VACCINATION; PERSISTENCE; RESPONSES; IMMUNITY
Dokumenten­typ
Position Paper
CC Lizenz
CC-BY
Open Access Type
Hybrid
ISSN/eISSN
2197-0378 - 2195-6405
DOI
Öffnen URL 10.1007/s40629-021-00178-2
WoS ID
Öffnen URL WOS:000698568500012
PubMed ID
Öffnen URL 34178577

Weitere Details

Band
30
Startseite
155
Letzte Seite
168
The vaccines against the coronavirus disease 2019 (COVID-19) approved in the European Union represent a decisive step in the fight against the pandemic. The application of these available vaccines to patients with pre-existing immunological conditions leads to a multitude of questions regarding efficacy, side effects and the necessary patient information.This review article provides insight into mechanisms of action of the currently available severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines and summarises the current state of science as well as expert recommendations regarding tolerability of the vaccines. In addition, the potential to develop protective immune responses is determined. A special focus is given on patients under immunosuppression or in treatment with immunomodulatory drugs. Special groups of the population such as children, pregnant women and the elderly are also considered.Despite the need for a patient-specific risk-benefit assessment, the consensus among experts is that patients with immunological diseases in particular benefit from the induced immune protection after COVID-19 vaccination and do not have an increased risk of side effects.© The Author(s) 2021.

Download
 RDF/XML-Format
 JSON-LD-Format
 Turtle-Format
 N3-Format